Mechanisms of Viral Resistance Mediated by MAP3K7 and CHD1 in Prostate Cancer
MAP3K7 和 CHD1 介导的前列腺癌病毒耐药机制
基本信息
- 批准号:9761274
- 负责人:
- 金额:$ 5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-08-01 至 2022-07-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAntiviral AgentsAntiviral ResponseAntiviral resistanceCHD1 geneCRISPR/Cas technologyCell LineCellsChIP-seqClinical DataDNA sequencingDataDisease remissionFailureGene ExpressionGene Expression RegulationGene ProteinsGene SilencingGenesGenetic TranscriptionGenetic TranslationImmuneImpairmentInterferonsIntravenousKnock-outLaboratoriesMAP3K7 geneMalignant NeoplasmsMalignant neoplasm of prostateMeasuresMediatingMediator of activation proteinMessenger RNAMethodsMusPC3 cell linePathogenicityPathway interactionsPhosphorylationPhosphotransferasesPolyribosomesPost-Transcriptional RegulationPredispositionProteasome InhibitionProteasome InhibitorProtein BiosynthesisProteinsRNA InterferenceResistanceRhabdoviridaeRoleSTAT1 geneSignal TransductionSystemTestingTissuesTransforming Growth Factor betaTropismVesicular stomatitis Indiana virusViralViral GenesViral ProteinsVirusVirus DiseasesWestern BlottingWorkXenograft procedurecancer cellcancer therapychromatin remodelingexperimental studygene productin vivoinsightmRNA Expressionnoveloncolytic Vesicular Stomatitis Virusoncolytic virotherapypathogenpre-clinicalprostate cancer cellprotein degradationprototyperesponsesmall hairpin RNAsuccesstissue tropismtranscriptome sequencingtumorviral resistance
项目摘要
Mechanisms of Viral Resistance Mediated by MAP3K7 and CHD1 in Prostate Cancer
A virus must evade or inhibit the defenses deployed by the host cell in order to replicate. This struggle between
host and pathogen is a determinant of viral tissue tropism and pathogenicity. Vesicular stomatitis virus (VSV),
the prototype rhabdovirus, is a virus whose tissue tropism is dictated by the host anti-viral response, and VSV's
success or failure in suppressing that response. For example, VSV selectively infects the immune-impaired
cells of cancer tissue. This is the basis for the use of VSV and other viruses as potential oncolytic virus
therapies. VSV is able to infect most cancers, however some cancers maintain resistance to VSV infection by
constitutively expressing anti-viral genes.
Prostate cancers (PCa) display variable levels of resistance to viral infection. Our laboratory has shown
that PC-3 cells constitutively express anti-viral gene products. Our data indicate that this is the result of a novel
anti-viral signaling mechanism that is mediated by the gene products of MAP3K7 and CHD1. When these
genes are silenced, PC-3 cells become more susceptible to viral infection. RNA-Seq analysis shows that
silencing CHD1 or both MAP3K7 and CHD1 decreases anti-viral gene mRNA expression, but silencing
MAP3K7 alone increases it. Silencing MAP3K7 decreases phosphorylation of STAT1. This suggests that
MAP3K7 regulates anti-viral gene expression in a post-transcriptional manner. Viral susceptibility and anti-viral
gene expression will be measured in PC-3 cells in which MAP3K7 and/or CHD1 have been knocked out with
the CRISPR/Cas9 system. The mechanism of post-transcriptional regulation of anti-viral genes by MAP3K7 will
be determined through Polysome-Seq and proteasome inhibition. Downstream mediators of the anti-viral effect
of MAP3K7 and CHD1 will be identified with ChIP-Seq. Finally, xenografts of PC-3 tumors with MAP3K7,
CHD1, or both knocked out will be established in mice. The mice will be treated with intravenous VSV, and any
effect of MAP3K7 or CHD1 on the tumors' response will be determined.
MAP 3 K7和CHD 1介导的前列腺癌病毒耐药机制
病毒必须逃避或抑制宿主细胞部署的防御才能进行复制。这场斗争,
是病毒组织嗜性和致病性决定因素。水泡性口炎病毒(VSV),
原型弹状病毒是一种病毒,其组织嗜性由宿主的抗病毒反应决定,而VSV的
成功或失败抑制反应。例如,VSV选择性地感染免疫受损的人,
癌组织的细胞。这是使用VSV和其他病毒作为潜在溶瘤病毒的基础
治疗VSV能够感染大多数癌症,然而,一些癌症通过以下方式保持对VSV感染的抗性:
组成型表达抗病毒基因。
前列腺癌(PCa)对病毒感染表现出不同程度的抵抗力。我们的实验室已经证明
PC-3细胞组成型表达抗病毒基因产物。我们的数据表明,这是一种新的结果,
MAP 3 K7和CHD 1基因产物介导的抗病毒信号传导机制。当这些
基因沉默,PC-3细胞变得更容易受到病毒感染。RNA-Seq分析显示,
沉默CHD 1或MAP 3 K7和CHD 1两者降低抗病毒基因mRNA表达,但沉默
沉默MAP 3 K7可降低STAT 1的磷酸化水平。这表明
MAP 3 K7以转录后方式调节抗病毒基因表达。病毒易感性和抗病毒
将在PC-3细胞中测量基因表达,其中MAP 3 K7和/或CHD 1已被用
CRISPR/Cas9系统MAP 3 K7对抗病毒基因转录后调控机制的研究将有助于进一步阐明MAP 3 K7的抗病毒基因转录后调控机制。
通过Polysome-Seq和蛋白酶体抑制来确定。抗病毒作用的下游介质
将用ChIP-Seq鉴定MAP 3 K7和CHD 1的表达。最后,用MAP 3 K7,
将在小鼠中建立CHD 1或两者敲除。小鼠将用静脉内VSV治疗,并且任何VSV治疗都将在小鼠体内进行。
将确定MAP 3 K7或CHD 1对肿瘤应答的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert Bayne其他文献
Robert Bayne的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 5万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 5万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 5万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 5万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 5万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 5万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 5万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 5万 - 项目类别: